Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (Nasdaq: NRIX) presented preclinical data for GS-6791, a novel IRAK4 protein degrader, at the EADV Congress in Paris. The data demonstrates the drug's effectiveness in treating inflammatory diseases through potent IRAK4 degradation and inhibition of IL-1 and IL-36 signaling pathways.
Key findings show that GS-6791 achieved near-complete IRAK4 knockdown in human blood and keratinocytes, reduced proinflammatory cytokines, and improved barrier function in dermatitis models. The compound, developed in collaboration with Gilead Sciences, is currently in a Phase 1 clinical trial evaluating its safety and tolerability in healthy volunteers.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in multiple investor conferences during September 2025.
The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website.
Nurix Therapeutics (Nasdaq: NRIX) reported significant progress in Q2 2025, highlighted by positive clinical developments and strategic collaborations. The company presented updated data for bexobrutideg (NX-5948), showing an impressive 80.9% objective response rate in r/r CLL patients. Nurix secured a $15M license fee from Sanofi's STAT6 collaboration extension and received FDA clearance for IRAK4 degrader GS-6791/NX-0479.
Financial highlights include Q2 2025 revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. R&D expenses increased to $78.1M from $48.9M, while net loss improved to $43.5M ($0.52 per share) compared to $44.5M ($0.71 per share) in Q2 2024.
Nurix Therapeutics (Nasdaq: NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation from the European Medicines Agency for treating lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).
The designation provides significant benefits including 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees. Bexobrutideg, an oral BTK degrader, is currently in Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies.
The drug has already received multiple regulatory designations, including FDA Fast Track for WM and CLL/SLL treatment, and EMA PRIME designation for CLL/SLL treatment, demonstrating strong regulatory momentum.
Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.